Clinical Takeaway
In this phase 3 randomized controlled trial, 820 adults with chronic low back pain received either VER-01, a full-spectrum cannabis extract, or placebo over 12 weeks, with extensions up to approximately one year. The trial was designed to generate high-quality evidence on both efficacy and safety in a condition where existing medications frequently fall short. Results from this large, well-structured study will help clarify whether full-spectrum cannabis preparations represent a viable clinical option for patients with chronic low back pain who have not responded adequately to conventional treatments.
#1 Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.
Citation: Karst Matthias et al.. Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial.. Nature medicine. 2025. PMID: 41023483.
Design: 5 Journal: 4 N: 2 Recency: 2 Pop: 2 Human: 1 Risk: -2
This phase 3 trial addresses a critical clinical gap by evaluating a full-spectrum cannabis extract as a potential alternative to opioids and NSAIDs for chronic low back pain, a condition affecting over 500 million people globally with inadequate current treatment options. The rigorous double-blind, placebo-controlled design with 820 participants provides robust evidence needed to establish whether cannabis-derived therapeutics can offer efficacy and safety advantages over existing pharmacologic approaches for CLBP management.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Open-label design — placebo effect not excluded
Abstract: Chronic low back pain (CLBP) affects over half a billion people worldwide. Current pharmacologic treatments offer limited efficacy and carry substantial risks, warranting the development of safe and effective alternatives. This multicenter, randomized, placebo-controlled phase 3 trial evaluated the efficacy and safety of VER-01 in CLBP. It enrolled 820 adults with CLBP (VER-01, n = 394; placebo, n = 426) and included a double-blind 12-week treatment phase (phase A), a 6-month open-label extension (phase B), followed by either a 6-month continuation (phase C) or randomized withdrawal (phase D). The primary endpoint of phase A was a change in mean numeric rating scale (NRS) pain intensity, with a change in total neuropathic pain symptom inventory (NPSI) score as a key secondary endpoint in participants with a neuropathic pain component (PainDETECT > 18). The primary endpoint for phase D was time to treatment failure. The study met its primary endpoint in phase A, with a mean pain reduction of -1.9 NRS points in the VER-01 group (mean difference (MD) versus placebo = -0.6, 95% confidence interval (CI) = -0.9 to -0.3; P < 0.001). Pain further decreased to -2.9 NRS points in phase B, with effects sustained through phase C. The study also met its key secondary endpoint of phase A, with a mean NPSI decrease of -14.4 (standard error, 3.3) points from baseline in the VER-01 arm (MD versus placebo = -7.3, 95% CI = -13.2 to -1.3; P = 0.017). Although phase D did not meet its primary endpoint (hazard ratio = 0.75, 95% CI = 0.44-1.27; P = 0.288), pain increased significantly more with placebo upon withdrawal (MD = 0.5, 95% CI = 0.0-1.0; P = 0.034). In phase A, the incidence of adverse events-mostly mild to moderate and transient-was higher with VER-01 than with placebo (83.3% versus 67.3%; P < 0.001). VER-01 was well-tolerated, with no signs of dependence or withdrawal. VER-01 shows potential as a new, safe and effective treatment for CLBP. ClinicalTrials.gov registration: NCT04
💊 This phase 3 trial demonstrates that full-spectrum cannabis extract VER-01 shows meaningful efficacy for chronic low back pain in a reasonably sized population, addressing a genuine clinical need given the limitations of conventional analgesics. However, practitioners should note several important caveats: the study population likely represents a selected group willing to enroll in cannabis research, the 12-week primary phase may not capture longer-term efficacy or tolerance patterns (particularly given the 6-month open-label extension), and full-spectrum extracts contain variable cannabinoid and terpene profiles that complicate standardization and reproducibility across different products. The safety profile and comparison to standard-of-care interventions like physical therapy or multimodal approaches remain key questions for clinical decision-making. For appropriate patients with CLBP who have failed or cannot tolerate conventional treatments, this evidence provides support for considering standardized full-spectrum cannabis extracts as part of an integrated pain management plan, though clinicians should counsel patients on the still-evol